Literature DB >> 20682644

Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype.

Anju Singh1, Hailong Wu, Ping Zhang, Christine Happel, Jinfang Ma, Shyam Biswal.   

Abstract

ATP-binding cassette, subfamily G, member 2 (ABCG2) is expressed in both normal and cancer cells and plays a crucial role in side population (SP) formation and efflux of xenobiotics and drugs. Nrf2, a redox-sensing transcription factor, on constitutive activation in non-small-cell lung cancer cells upregulates a wide spectrum of genes involved in redox balance, glutathione metabolism, and drug detoxification, which contribute to chemoresistance and tumorigenicity. This study examined the mechanism underlying Nrf2-dependent expression of ABCG2 and its role in the multidrug resistance phenotype. In silico analysis of the 5'-promoter flanking region of ABCG2 identified an antioxidant response element (ARE) at -431 to -420 bp. A detailed promoter analysis using luciferase reporter assays showed that ARE at -431 to -420 bp is critical for the Nrf2-mediated expression in lung cancer cells. Electrophoretic mobility shift assays and chromatin immunoprecipitation assays revealed that Nrf2 interacts with the ABCG2 ARE element at -431 to -420 bp in vitro and in vivo. Disruption of Nrf2 expression in lung and prostate cancer cells, by short hairpin RNA, attenuated the expression of ABCG2 transcript and protein, and dramatically reduced the SP fraction in Nrf2-depleted cancer cells. Moreover, depleted levels of ABCG2 in these Nrf2 knockdown cells sensitized them to mitoxantrone and topotecan, two chemotherapy drugs detoxified mainly by ABCG2. As expected, overexpression of Nrf2 cDNA in lung epithelial cells led to an increase in ABCG2 expression and a 2-fold higher SP fraction. Thus, Nrf2-mediated regulation of ABCG2 expression maintains the SP fraction and confers chemoresistance. (c) 2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20682644      PMCID: PMC2955865          DOI: 10.1158/1535-7163.MCT-10-0108

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  46 in total

1.  Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice.

Authors:  M Ramos-Gomez; M K Kwak; P M Dolan; K Itoh; M Yamamoto; P Talalay; T W Kensler
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

2.  The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors.

Authors:  Christian W Scharenberg; Michael A Harkey; Beverly Torok-Storb
Journal:  Blood       Date:  2002-01-15       Impact factor: 22.113

3.  A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia.

Authors:  G G Wulf; R Y Wang; I Kuehnle; D Weidner; F Marini; M K Brenner; M Andreeff; M A Goodell
Journal:  Blood       Date:  2001-08-15       Impact factor: 22.113

4.  The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype.

Authors:  S Zhou; J D Schuetz; K D Bunting; A M Colapietro; J Sampath; J J Morris; I Lagutina; G C Grosveld; M Osawa; H Nakauchi; B P Sorrentino
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

5.  Nrf2 regulates the sensitivity of death receptor signals by affecting intracellular glutathione levels.

Authors:  Naoki Morito; Keigyou Yoh; Ken Itoh; Aki Hirayama; Akio Koyama; Masayuki Yamamoto; Satoru Takahashi
Journal:  Oncogene       Date:  2003-12-18       Impact factor: 9.867

6.  Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts.

Authors:  Asako Hayashi; Hiroshi Suzuki; Ken Itoh; Masayuki Yamamoto; Yuichi Sugiyama
Journal:  Biochem Biophys Res Commun       Date:  2003-10-24       Impact factor: 3.575

7.  A stem cell molecular signature.

Authors:  Natalia B Ivanova; John T Dimos; Christoph Schaniel; Jason A Hackney; Kateri A Moore; Ihor R Lemischka
Journal:  Science       Date:  2002-09-12       Impact factor: 47.728

8.  Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer.

Authors:  Tatsuhiro Shibata; Akiko Kokubu; Masahiro Gotoh; Hidenori Ojima; Tsutomu Ohta; Masayuki Yamamoto; Setsuo Hirohashi
Journal:  Gastroenterology       Date:  2008-07-03       Impact factor: 22.682

9.  Induction of phase 2 enzymes by serum oxidized polyamines through activation of Nrf2: effect of the polyamine metabolite acrolein.

Authors:  Mi-Kyoung Kwak; Thomas W Kensler; Robert A Casero
Journal:  Biochem Biophys Res Commun       Date:  2003-06-06       Impact factor: 3.575

Review 10.  Regulatory mechanisms controlling gene expression mediated by the antioxidant response element.

Authors:  Truyen Nguyen; Philip J Sherratt; Cecil B Pickett
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002-01-10       Impact factor: 13.820

View more
  70 in total

1.  Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype.

Authors:  Kaijie He; Tong Xu; Amir Goldkorn
Journal:  Mol Cancer Ther       Date:  2011-04-25       Impact factor: 6.261

2.  Cell-type selective phototoxicity achieved with chlorophyll-a derived photosensitizers in a co-culture system of primary human tumor and normal lung cells.

Authors:  Erin C Tracy; Mary J Bowman; Ravindra K Pandey; Barbara W Henderson; Heinz Baumann
Journal:  Photochem Photobiol       Date:  2011-10-03       Impact factor: 3.421

Review 3.  Transcription factor-mediated regulation of the BCRP/ABCG2 efflux transporter: a review across tissues and species.

Authors:  Ludwik Gorczyca; Lauren M Aleksunes
Journal:  Expert Opin Drug Metab Toxicol       Date:  2020-03-14       Impact factor: 4.481

Review 4.  Tumor cell survival pathways activated by photodynamic therapy: a molecular basis for pharmacological inhibition strategies.

Authors:  Mans Broekgaarden; Ruud Weijer; Thomas M van Gulik; Michael R Hamblin; Michal Heger
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

Review 5.  Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance.

Authors:  Karthika Natarajan; Yi Xie; Maria R Baer; Douglas D Ross
Journal:  Biochem Pharmacol       Date:  2012-01-11       Impact factor: 5.858

6.  miR-99a directly targets the mTOR signalling pathway in breast cancer side population cells.

Authors:  Z Yang; Y Han; K Cheng; G Zhang; X Wang
Journal:  Cell Prolif       Date:  2014-10-27       Impact factor: 6.831

Review 7.  Unraveling the journey of cancer stem cells from origin to metastasis.

Authors:  Rama Krishna Nimmakayala; Surinder K Batra; Moorthy P Ponnusamy
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-11-09       Impact factor: 10.680

8.  Rare Variants in the ABCG2 Promoter Modulate In Vivo Activity.

Authors:  Rachel J Eclov; Mee J Kim; Robin Smith; Nadav Ahituv; Deanna L Kroetz
Journal:  Drug Metab Dispos       Date:  2018-02-21       Impact factor: 3.922

Review 9.  Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Med       Date:  2011-05-20       Impact factor: 6.354

Review 10.  Inflammation and pancreatic cancer: disease promoter and new therapeutic target.

Authors:  Shin Hamada; Atsushi Masamune; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2013-11-30       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.